Table 4.
Patients stratified into optimal or non-optimal testosterone levels and compared to PSA statistics
| Non-optimal | Optimal | |||
|---|---|---|---|---|
| Group | ||||
| LHRH agonist alone | PSA | No. patients | 10 | 37 |
| Minimum | 0.82 | 0.09 | ||
| Q1 | 1.23 | 0.10 | ||
| Median | 2.59 | 0.35 | ||
| Q3 | 17.95 | 1.93 | ||
| Maximum | 88.60 | 62.61 | ||
| MAB patients | PSA | No. patients | 4 | 18 |
| Minimum | 16.20 | 0.10 | ||
| Q1 | 65.10 | 0.27 | ||
| Median | 114.00 | 13.28 | ||
| Q3 | 138.00 | 88.34 | ||
| Maximum | 162.00 | 1049.00 |
PSA: prostate-specific antigen; LHRH: luteinizing hormone releasing-hormone; Q1: first quartile; Q3: third quartile; MAB: maximal androgen blockade.